Powered by 
Translate
Translate
Reach Non-regulatory
9 October 2023
N4 Pharma Plc
("N4 Pharma" or the "Company")
Investor Presentation via Investor Meet Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, is pleased to announce that Nigel Theobald (CEO) and Paul Murray (Nanogenics) will provide an update following the Company's acquisition of Nanogenics via a live presentation on the Investor Meet Company platform on 16 October 2023 at 2.00pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma Plc via:
https://www.investormeetcompany.com/n4-pharma-plc/register-investor
Investors who already follow N4 Pharma Plc on the Investor Meet Company platform will automatically be invited.
Enquiries:
|
N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director
|
Via IFC Advisory |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking)
|
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker
|
Tel: +44 (0)20 3657 0050 |
|
IFC Advisory Limited Financial PR Graham Herring Zach Cohen |
Tel: +44 (0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
